Glaucoma Nonhuman Primates Disease Model

Glaucoma is a debilitating eye disease that can lead to irreversible vision loss due to damage to the optic nerve. Ocular hypertension is one of the most important risk factors in glaucoma development. Prisys Biotechnologies offers a nonhuman primate model of glaucoma induced by anterior chamber injection. This model has a standard study duration of 15-20 weeks and includes clinical endpoints such as IOP measurement, slit-lamp examination, color funduscope examination, eyeball biopsy, histopathology, clinical observation, and OCT examination under dexamethasone eye drops. The model produces human-similar manifestations of glaucoma and allows for controlled elevation of IOP. Clinical ophthalmic examinations are also conducted to assess disease progression and treatment efficacy.

The Prisys Biotechnologies NHP model of Anterior chamber injection induced glaucoma allows for controlled elevation of IOP and closely mimics human disease manifestation. The standard study duration of 15-20 weeks allows for comprehensive evaluation of the disease course, with clinical endpoints including IOP, slit-lamp examination, color funduscope examination, eyeball biopsy, histopathology, clinical observation, and OCT examination under dexamethasone eye drops. The model provides a valuable tool for investigating the pathogenesis of glaucoma and testing potential therapies.

Hot Tags: glaucoma nonhuman primates disease model, research, study, monkey, gene therapy, NHP Asthma Dermatitis Model, antibody PD pharmacology, AMD Nonhuman Primates, NHP biosafety pharmacology, NHP DMPK pharmacology, NHP Efficacy pharmacology